BioMarin Pharmaceutical
BioMarin Pharmaceutical

BioMarin Pharmaceutical

Biotechnology
WebsiteInvestor RelationsSEC
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

$10.7B

Market Cap • 10/7/2026

1996

(30 years)

Founded

1999

(27 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,7

P/S

3,1

P/EBITDA

35,4

P/OCF

12,5

P/FCF

14,5

P/E

149,2

BVPS

32,7

EPS

0,4

Market Cap

Market Cap

10,7B

EV

14B

EV/Revenue

4,1

EV/EBITDA

46,3

EV/EBIT

93,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0,3%

Total Yield

0,3%

Payout

0%

Retained Earnings

304,5M

Profitability

Gross Margin

76,1%

EBITDA Margin

8,9%

EBIT Margin

4,4%

Net Margin

2,1%

D&A/EBITDA

29%

R&D/Revenue

29%

Capex/Revenue

3,5%

Capex/D&A

77,7%

Capex/OCF

13,9%

SBC/OCF

25,1%

% PPE

8,4%

% Goodwill

5,6%

ROE

1,2%

ROIC

—

Growth

CAGR Revenue 5Y

12,2%

CAGR Net Income 5Y

-38,5%

CAGR EPS 5Y

-38,7%

CAGR OCF 5Y

26,1%

Leverage

N.D./EBITDA

11

Debt/Equity

0%

Current Ratio

2,4

Quick Ratio

1,2

Interest Coverage

178,5%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium